Literature DB >> 26225613

Pain management framework in the emergency department: patterns in 40 emergency departments worldwide.

Adam J Parnass1, Nathaniel R Greenbaum, Michael A Glick, Pinchas Halpern.   

Abstract

Many studies illustrate variation in pain management protocols in emergency medicine. This study examines analgesia frameworks in emergency departments (EDs) in multiple countries, compares them with the recent literature, and illuminates the variability in protocols and treatment. A survey was conducted assessing the pain management framework and practices in a convenience sample of 40 hospitals distributed over 22 countries. Most EDs (80%) indicated that pain intensity was routinely documented, most commonly (42.5%) using a verbal numerical 0-10 scale. Most (57.5%) reported specific protocols for specific conditions, with 56.5% reporting that these protocols were mandatory. Structured training was reported by 27.5% of responders. All (100%) reported analgesia administration in the trauma room. Oral paracetamol (67.5%) and intravenous morphine (92.5%) were the most commonly used analgesics. The variability in the pain management framework is high among EDs worldwide, highlighting the need for more international uniformity in analgesia practices in the ED.

Entities:  

Mesh:

Year:  2016        PMID: 26225613     DOI: 10.1097/MEJ.0000000000000299

Source DB:  PubMed          Journal:  Eur J Emerg Med        ISSN: 0969-9546            Impact factor:   2.799


  2 in total

1.  Increased analgesia administration in emergency medicine after implementation of revised guidelines.

Authors:  Geesje Van Woerden; Crispijn L Van Den Brand; Cornelis F Den Hartog; Floris J Idenburg; Diana C Grootendorst; M Christien Van Der Linden
Journal:  Int J Emerg Med       Date:  2016-02-10

2.  Attributes of analgesics for emergency pain relief: results of the Consensus on Management of Pain Caused by Trauma Delphi initiative.

Authors:  Keith Porter; Bart Morlion; Mark Rolfe; Christoph Dodt
Journal:  Eur J Emerg Med       Date:  2020-02       Impact factor: 4.106

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.